
Sign up to save your podcasts
Or
In his weekly clinical update, Dr. Griffin begins with discussing if the antibiotic neomycin is really a pan-antiviral countermeasure, then reviews the recent statistics on SARS-CoV-2 infection before deep diving into if shedding and the rapid antigen test results correlate, the guidelines for spring administration of COVID vaccines boosters, whether COVID booster associates with the long COVID prevalence, discusses the emergency use application of a pre-exposure prophylactic, revised guidelines for how to treat respiratory viral infection guidelines by the CDC, the caveats for improper use of antibiotics to treat SARS-CoV-2 (a viral infection), continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if administration of an anti-immunoglobulin E monoclonal antibody can be used for COVID-19 treatment, if inhibiting T-cell activation will reduce secretion and production of inflammatory cytokines including IL-6, if changes in the gut microbiome associate with post -acute COVID-19 syndrome, and the pulmonary and neurologic determinants of long COVID-19 such as the presence of neurofilament light chain in plasma. For more information about this body of work, listen to TWiV 1088.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
4.8
20202,020 ratings
In his weekly clinical update, Dr. Griffin begins with discussing if the antibiotic neomycin is really a pan-antiviral countermeasure, then reviews the recent statistics on SARS-CoV-2 infection before deep diving into if shedding and the rapid antigen test results correlate, the guidelines for spring administration of COVID vaccines boosters, whether COVID booster associates with the long COVID prevalence, discusses the emergency use application of a pre-exposure prophylactic, revised guidelines for how to treat respiratory viral infection guidelines by the CDC, the caveats for improper use of antibiotics to treat SARS-CoV-2 (a viral infection), continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if administration of an anti-immunoglobulin E monoclonal antibody can be used for COVID-19 treatment, if inhibiting T-cell activation will reduce secretion and production of inflammatory cytokines including IL-6, if changes in the gut microbiome associate with post -acute COVID-19 syndrome, and the pulmonary and neurologic determinants of long COVID-19 such as the presence of neurofilament light chain in plasma. For more information about this body of work, listen to TWiV 1088.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
6,089 Listeners
9,104 Listeners
806 Listeners
29 Listeners
43,901 Listeners
90,609 Listeners
35 Listeners
12 Listeners
454 Listeners
20 Listeners
4 Listeners
4 Listeners
511 Listeners
6,289 Listeners
25 Listeners
226 Listeners
270 Listeners
170 Listeners
99 Listeners
15,285 Listeners
78 Listeners
48 Listeners